Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
TipRanksApr 27 07:35 ET
Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
BenzingaApr 25 07:25 ET
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 663.36% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/01/2024 663.36% HC Wainwright & Co. →
BenzingaApr 25 07:24 ET
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
TipRanksApr 25 06:25 ET
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics (CAPR) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duch
MT NewswiresApr 24 15:21 ET
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Yahoo FinanceApr 24 12:42 ET
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals Among Healthcare Movers
Seeking AlphaApr 24 10:00 ET
Express News | Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla
Moomoo 24/7Apr 24 09:05 ET
Express News | Capricor Therapeutics: FDA Feedback Supports Requests for Pre-Bla Meeting,Subsequent Rolling Bla Submission Following Upcoming Q2 Type-B FDA Meeting
Moomoo 24/7Apr 24 09:04 ET
Express News | Capricor Therapeutics: Aligned With FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility
Moomoo 24/7Apr 24 09:04 ET
Express News | Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Moomoo 24/7Apr 24 09:04 ET
Express News | Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
Moomoo 24/7Apr 24 09:00 ET
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 10:29 ET
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Catapults 51% Though Its Price And Business Still Lag The Industry
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares have had a really impressive month, gaining 51% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up
Simply Wall StApr 3 06:55 ET
Solid Biosciences Gets FDA Rare Pediatric Disease Status for DMD Therapy
Seeking AlphaApr 1 10:17 ET
Canopy Growth, Capricor Therapeutics, GT Biopharma Among Healthcare Movers
Seeking AlphaMar 22 10:00 ET
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare
GlobeNewswireMar 21 08:30 ET
This Just In: Analysts Are Boosting Their Capricor Therapeutics, Inc. (NASDAQ:CAPR) Outlook for This Year
Shareholders in Capricor Therapeutics, Inc. (NASDAQ:CAPR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased
Simply Wall StMar 16 08:59 ET
Catalyst Announces US Launch of Duchenne MD Drug Agamree
Seeking AlphaMar 13 13:46 ET
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Yahoo FinanceMar 13 09:40 ET
No Data
No Data